- $79.45m
- $61.14m
- $90.50m
Brief: Pulmonx Reports Q4 And Full Year 2021 Financial Results
Pulmonx Corp expected to post a loss of 36 cents a share - Earnings Preview
Brief: Pulmonx Posts Q3 Loss Per Share Of $0.28
Pulmonx Corp expected to post a loss of 37 cents a share - Earnings Preview
Brief: Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage For Severe COPD/Emphysema Treatment
Pulmonx Corp reports results for the quarter ended in June - Earnings Summary
Brief: Pulmonx Reports Q2 2021 Financial Results
Brief: Pulmonx Welcomes Two New Board Members
Pulmonx Corp expected to post a loss of 37 cents a share - Earnings Preview
Brief: Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits Of Zephyr Valve For Patients With Severe Copd/Emphysema
Pulmonx Corp reports results for the quarter ended in March - Earnings Summary
Brief: Pulmonx Q1 Revenue Rose 7% To $9.2 Million
Brief: Pulmonx Posts Q4 Loss Per Share Of $0.27
Brief: Pulmonx Reports Third Quarter 2020 Financial Results
Pulmonx: More than doubles in Nasdaq debut
Brief: Pulmonx announces Pricing Of Its Upsized Initial Public Offering Of 10,000,000 Shares Of Its Common Stock At $19.00 Per Share
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:02 AM